John Orwin

John Orwin joined Samsara BioCapital as a Venture Partner in June, 2024 and has over 35 years of experience in the pharmaceutical and biotechnology industries. John Orwin serves on the Board of Directors of Travere Therapeutics, Cargo Therapeutics (Chair), AnaptysBio (Chair) and Nested Therapeutics (Chair). He previously served on the Board of Directors of Array BioPharma, Inc. and Seagen, Inc. He served as president and CEO of Atreca, Inc., a clinical-stage biotechnology company, and previously was the CEO of Relypsa, until its acquisition by Galenica, and CEO of Affymax. In building successful businesses and commercializing a range of blockbuster products, Mr. Orwin has held leadership roles in marketing, sales, and operations for Genentech, Johnson & Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer, and Schering-Plough Corporation. Mr. Orwin holds a master’s degree in business administration from New York University and a bachelor’s degree in economics from Rutgers University.